Running a 2,000 patient study, with average risk patients in the U.S., to read out by the end of 2025 (eAArly DETECT 2). With eAArly DETECT 2, the Company addresses FDA feedback and prepares for a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback